In other solid tumors, BRCA1/2, PALB2, or RAD51-mutated cancers have demonstrated sensitivity to platinum-based chemotherapy and PARP inhibition, supporting the rationale for evaluating similar approaches in pNENs [76,77,78,79]. This evidence concerns the gene PALB2 and cancer.